Search Result

Results for "

genotype 1b HCV

" in MedChemExpress (MCE) Product Catalog:

By Targets:	HCV (39) HCV Protease (14) Antibiotic (2) Cyclophilin (1) DNA/RNA Synthesis (7) Drug Derivative (1) Endogenous Metabolite (1) HBV (1) Isotope-Labeled Compounds (4) PI4K (1) Ras (1) Reference Standards (6) SARS-CoV (2)
By Research Areas:	Cancer (2) Infection (45) Inflammation/Immunology (2)

Inhibitors & Agonists

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Targets Recommended: HCV HCV Protease

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N6798

Myriocin 10+ Cited Publications Thermozymocidin; ISP-I	HCV Antibiotic	Infection
Myriocin (Thermozymocidin), a fungal metabolite could be isolated from Myriococcum albomyces, Isaria sinclairi and Mycelia sterilia, is a potent inhibitor of serine-palmitoyl-transferase (SPT) and a key enzyme in de novo synthesis of sphingolipids. Myriocin suppresses replication of both the subgenomic HCV-1b replicon and the JFH-1 strain of genotype 2a infectious HCV, with an IC₅₀ of 3.5 μg/mL for inhibiting HCV infection .

HY-15789

Elbasvir 5+ Cited Publications MK-8742	HCV	Infection
Elbasvir (MK-8742) is a hepatitis C virus nonstructural protein 5A (HCV NS5A) inhibitor with EC₅₀s of 4, 3 and 3 nM against genotype 1a, 1b, and 2a, respectively.

HY-10466

Daclatasvir Maximum Cited Publications 47 Publications Verification BMS-790052; EBP 883	HCV	Infection
Daclatasvir (BMS-790052) is a potent and orally active HCV NS5A protein inhibitor with EC₅₀s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir is also a organic anion transporting polypeptide 1B (OATP1B) and *OATP1B3* inhibitor with IC₅₀s of 1.5 µM and 3.27 µM, respectively .

HY-19840

Voxilaprevir GS-9857	HCV Protease	Infection Cancer
Voxilaprevir (GS-9857) is a noncovalent, reversible inhibitor of HCV NS3/4A protease inhibitor (PI) with pangenotypic antiviral activity . Voxilaprevir inhibits genotype 1b and 3a wild-type NS3 proteases with K_i values of 0.038 nM and 0.066 nM, respectively . Voxilaprevir is an orally active direct-acting antiviral agent (DAA) and can be used for HCV infection research .

HY-13998

Dasabuvir 10+ Cited Publications ABT-333	HCV DNA/RNA Synthesis	Infection
Dasabuvir (ABT-333) is a nonnucleoside *hepatitis C virus (HCV) polymerase* inhibitor. Dasabuvir inhibits RNA-dependent RNA polymerase encoded by the HCV NS5B gene. Dasabuvir inhibits genotype 1a (strain H77) and 1b (strain Con1) replicons, with EC₅₀ values of 7.7 and 1.8 nM, respectively .

HY-10238

Danoprevir 15+ Cited Publications ITMN-191; R7227; RO5190591; RG7227	HCV Protease HCV SARS-CoV	Infection
Danoprevir (ITMN-191) is an orally active NS3/4A protease inhibitor for hepatitis C virus (HCV) with an IC₅₀ of 0.29 nM and is selective for NS3/4A over a panel of 53 proteases (IC₅₀ higher than 10 μM). Danoprevir (ITMN-191) inhibits HCV genotypes 1a, 1b, 4, 5, and 6 (IC₅₀s=0.2-0.4 nM) as well as 2b and 3a (IC₅₀s=1.6, 3.5 nM) . Danoprevir is also a SARS-CoV 3CL ^pro inhibitor with an IC₅₀ of 0.05 μM .

HY-10465

Daclatasvir dihydrochloride Maximum Cited Publications 47 Publications Verification BMS-790052 dihydrochloride; EBP 883 dihydrochloride	HCV	Infection
Daclatasvir dihydrochloride (BMS-790052 dihydrochloride) is a potent and orally active HCV NS5A protein inhibitor with EC₅₀s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir dihydrochloride is also an organic anion transporting polypeptide 1B (OATP1B) and *OATP1B3* inhibitor with IC₅₀s of 1.5 μM and 3.27 μM, respectively .

HY-109035

Inarigivir soproxil 1 Publications Verification SB9200; GS-9992	HCV HBV	Infection
Inarigivir soproxil (SB9200) is an agonist of innate immunity and shows potent antiviral activity against resistant *HCV* variants, with EC₅₀s of 2.2 and 1.0 μM for HCV 1a/1b in cells of genotype 1 HCV replicon systems. Inarigivir soproxil, an orally bioavailable proagent of SB 9000, has broad-spectrum antiviral activity against RNA viruses including HCV, norovirus, respiratory syncytial virus and influenza and HBV .

HY-10242

Ciluprevir BILN 2061; BILN 2061ZW	HCV HCV Protease DNA/RNA Synthesis	Infection
Ciluprevir (BILN 2061; BILN 2061ZW) is an orally active macrocyclic peptide inhibitor of hepatitis C virus (HCV)NS3 protease, with an IC₅₀ of 3 nM. Ciluprevir has Kᵢ values of 0.66 nM and 0.30 nM against genotypes 1b and 1a, respectively. Ciluprevir inhibits HCV RNA replication with an EC₅₀ of 1.2 nM, and its EC50 values against genotypes 1b and 1a are 3 nM and 4 nM, respectively. Ciluprevir shows no significant inhibition against human leukocyte elastase and hepatic cathepsin B. Ciluprevir can be used for genotype 1 HCV infection .

HY-15256

Faldaprevir BI 201335	HCV Protease	Infection
Faldaprevir (BI 201335) is a potent, orally active and selective noncovalent inhibitor of NS3/4A protease of HCV (hepatitis C virus) genotypes 1a and 1b, with K_i values of 2.6 and 2.0 nM, respectively. Faldaprevir inhibits HCV RNA replication, with EC₅₀ values of 6.5 and 3.1 nM, respectively. Faldaprevir has potent antiviral activity against chronic HCV infection .

HY-13465

VCH-916 1 Publications Verification	HCV	Infection
VCH-916 is a thiophene derivative and non-nucleoside inhibitor of HCV NS5B polymerase with sub-micromolar IC₅₀ values versus genotype 1a and 1b replicons. VCH-916 binds to Thumb Site II. VCH-916 can be used for the research of hepatitis c virus (hcv) infection .

HY-10118

Filibuvir 4 Publications Verification	HCV DNA/RNA Synthesis	Infection
Filibuvir is an orally active, selective non-nucleoside inhibitor of the HCV nonstructural 5B protein (NS5B) RNA-dependent RNA polymerase (RdRp). Filibuvir binds noncovalently in the thumb II allosteric pocket of NS5B. Filibuvir inhibits genotype 1a and 1b replicons with EC₅₀s of 59 nM for both isoforms, respectively . Filibuvir preferentially inhibits elongative RNA synthesis and potently decreases viral RNA accumulation .

HY-147358

Yimitasvir diphosphate Emitasvir diphosphate; DAG-181 diphosphate	HCV	Infection
Yimitasvir diphosphate (Emitasvir diphosphate; DAG-181 diphosphate) is an orally active inhibitor of hepatitis C virus (HCV) nonstructural protein 5A (NS5A). Yimitasvir diphosphate is applicable to research related to HCV infection .

HY-10465R

Daclatasvir dihydrochloride (Standard) BMS-790052 dihydrochloride (Standard); EBP 883 dihydrochloride (Standard)	Reference Standards HCV	Infection
Daclatasvir (dihydrochloride) (Standard) is the analytical standard of Daclatasvir (dihydrochloride). This product is intended for research and analytical applications. Daclatasvir dihydrochloride (BMS-790052 dihydrochloride) is a potent and orally active HCV NS5A protein inhibitor with EC₅₀s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir dihydrochloride is also an organic anion transporting polypeptide 1B (OATP1B) and *OATP1B3* inhibitor with IC₅₀s of 1.5 µM and 3.27 µM, respectively .

HY-U00213

Furaprofen R803	HCV	Infection
Furaprofen (R803) is an effective HCV replication inhibitor. Furaprofen (R803) is substantially more potent against genotype 1a and 1b replicons (EC₅₀, ~30 nM) than against the genotype 2a replicon (EC₅₀, ~1,000 nM).

HY-147358A

Yimitasvir Emitasvir; DAG-181	HCV	Infection
Yimitasvir (Emitasvir; DAG-181) is an orally active inhibitor of hepatitis C virus (HCV) nonstructural protein 5A (NS5A). Yimitasvir is applicable to research related to HCV infection .

HY-102030

BMS-961955	HCV	Infection
BMS-961955 is an orally active inhibitor of *HCV* NS5B polymerase. BMS-961955 exhibits potent inhibitory activity against *HCV* genotype 1 (GT-1a/1b) replicons with EC₅₀s of 4.3 nM and 7.9 nM, respectively. BMS-961955 can be used for the study of HCV infection .

HY-131905S

BMS-986144	Isotope-Labeled Compounds HCV Protease HCV	Infection Inflammation/Immunology Cancer
BMS-986144 is a third-generation, pan-genotype (GT) NS3/4A protease inhibitor. BMS-986144 inhibits HCV replicon with EC₅₀s of 2.3, 0.7, 1.0, 12, 8.0, and 5.8 nM for GT-1a, GT-1b, GT-2a, GT-3a, 1a R155X, and 1b D168V, respectively. BMS-986144 has the potential for the research of HCV infection .

HY-13998A

Dasabuvir sodium ABT-333 sodium	HCV DNA/RNA Synthesis	Infection
Dasabuvir (ABT-333) sodium is a nonnucleoside *hepatitis C virus (HCV) polymerase* inhibitor. Dasabuvir sodium inhibits RNA-dependent RNA polymerase encoded by the HCV NS5B gene. Dasabuvir sodium inhibits genotype 1a (strain H77) and 1b (strain Con1) replicons, with EC₅₀ values of 7.7 and 1.8 nM, respectively .

HY-15789R

Elbasvir (Standard) MK-8742 (Standard)	Reference Standards HCV	Infection
Elbasvir (Standard) is the analytical standard of Elbasvir. This product is intended for research and analytical applications. Elbasvir (MK-8742) is a hepatitis C virus nonstructural protein 5A (HCV NS5A) inhibitor with EC₅₀s of 4, 3 and 3 nM against genotype 1a, 1b, and 2a, respectively.

HY-115982

NS5A-IN-3	HCV Protease	Infection
NS5A-IN-3 (Compound 15) is a potent inhibitor of NS5A. NS5A-IN-3 has extremely high potency against HCV genotype 1b, improved activity against genotype 3a (GT 3a) and good metabolic stability. NS5A-IN-3 exhibits a higher resistance barrier than daclatasvir against genotype 1b . NS5A-IN-3 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-19557

IDX-320	Drug Derivative HCV Protease	Infection
IDX-320 is a Pipecolic acid (HY-Y0669) derivative. IDX-320 inhibits NS3/4a proteases across genotypes 1a, 1b, 2a, and 4a with an IC₅₀ 0.8-1.9 nM. IDX-320 can be used in the research of HCV infection .

HY-136267

HCV-IN-30	HCV	Infection
HCV-IN-30 (compound 48) is a HCV NS5A replication complex inhibitor, with IC₅₀s of 901 and 102 nM for genotypes 1a and 1b replicons, respectively .

HY-150760

GSK5852 GSK2485852	HCV	Inflammation/Immunology
GSK5852 (GSK2485852) is an HCV NS5B polymerase inhibitor, with an IC₅₀ value of 50 nM. GSK5852 displays antiviral activity and inhibits HCV with EC₅₀s of 3.0 nM (genotype 1a, GT1a) and 1.7 nM (GT1b), respectively .

HY-147885

HCV-IN-41	HCV	Infection
HCV-IN-41 (compound 4) is a highly potent hepatitis C virus (HCV) inhibitor with an EC₅₀ value of 0.006762 nM, 5.183 nM, 1.365 nM and 142.2 nM for HCV genotype 1b, 2a, 3a and 4a, respectively. HCV-IN-41 reduces HCV RNA replication .

HY-19921

JTK-853	HCV	Infection
JTK-853 is a novel, non-nucleoside Hepatitis C Virus (HCV) polymerase inhibitor which shows effective antiviral activity in HCV replicon cells with EC₅₀s of 0.38 and 0.035 µM in genotype 1a H77 and 1b Con1 strains, respectively.

HY-125473

IDX375	Endogenous Metabolite	Infection
IDX375 is a novel non-nucleoside inhibitor with selective inhibitory activity against HCV NS5B. IDX375 has good selectivity for genotypes 1a and 1b. The structure and binding site of IDX375 were confirmed by X-ray cocrystal studies .

HY-15256A

Faldaprevir sodium BI 201335 sodium	HCV Protease	Infection
Faldaprevir sodium is a potent, orally active and selective noncovalent inhibitor of NS3/4A protease of HCV (hepatitis C virus) genotypes 1a and 1b, with K_i values of 2.6 and 2.0 nM, respectively. Faldaprevir sodium inhibits HCV RNA replication, with EC₅₀ values of 6.5 and 3.1 nM, respectively. Faldaprevir sodium has potent antiviral activity against chronic HCV infection .

HY-125182

SMCypI C31	Cyclophilin HCV	Infection
SMCypI C31 is a non-peptidic cyclophilin inhibitor with potent peptidyl-prolyl cis/trans isomerases (PPIase) inhibitory activity (IC₅₀ of 0.1 µM). SMCypI C31 shows pangenotype anti-HCV activity with EC₅₀s ranging from 1.20 to 7.76 μM for genotype 1a, 1b, 2a, 3a, and 5a HCV subgenomic replicons (HCV-SGRs) and chimeric genotype 2a/4a HCV-SGRs. SMCypI C31 disrupts the cyclophilin A-NS5A interaction .

HY-19932

MK-2748	HCV Protease HCV	Infection
MK-2748 is a hepatitis C virus (HCV) NS3/4a protease inhibitor. MK-2748 exhibits broad-spectrum and potent antiviral activity, with nanomolar-level activity against all genotypes (gt1a-gt6) (IC₅₀ < 0.115 nM), showing only slightly weaker activity against gt3a (1.212 nM), and maintaining high inhibitory activity against drug-resistant mutant strains such as gt1b R155K (IC₅₀ = 0.032 nM) and D168Y (IC₅₀ = 0.057 nM). MK-2748 can be used in the research of HCV infection .

HY-10466S

Daclatasvir-d6 BMS-790052-d₆; EBP 883-d₆	Isotope-Labeled Compounds HCV	Infection
Daclatasvir-d₆ is deuterium labeled Daclatasvir. Daclatasvir (BMS-790052) is a potent and orally active HCV NS5A protein inhibitor with EC₅₀s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir is also a organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC₅₀s of 1.5 μM and 3.27 μM, respectively .

HY-10466S2

Daclatasvir-d16 BMS-790052-d₁₆; EBP 883-d₁₆	Isotope-Labeled Compounds HCV	Infection
Daclatasvir-d₁₆ is deuterium labeled Daclatasvir. Daclatasvir (BMS-790052) is a potent and orally active HCV NS5A protein inhibitor with EC₅₀s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir is also a organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC₅₀s of 1.5 μM and 3.27 μM, respectively .

HY-N6798R

Myriocin (Standard) Thermozymocidin (Standard); ISP-I (Standard)	Reference Standards HCV Antibiotic	Infection
Myriocin (Standard) is the analytical standard of Myriocin. This product is intended for research and analytical applications. Myriocin (Thermozymocidin), a fungal metabolite could be isolated from Myriococcum albomyces, Isaria sinclairi and Mycelia sterilia, is a potent inhibitor of serine-palmitoyl-transferase (SPT) and a key enzyme in de novo synthesis of sphingolipids. Myriocin suppresses replication of both the subgenomic HCV-1b replicon and the JFH-1 strain of genotype 2a infectious HCV, with an IC50 of 3.5 μg/mL for inhibiting HCV infection[1][2][3].

HY-10466R

Daclatasvir (Standard) BMS-790052 (Standard); EBP 883 (Standard)	Reference Standards HCV	Infection
Daclatasvir (Standard) is the analytical standard of Daclatasvir. This product is intended for research and analytical applications. Daclatasvir (BMS-790052) is a potent and orally active HCV NS5A protein inhibitor with EC50s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir is also a organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC50s of 1.5 µM and 3.27 µM, respectively .

HY-13998R

Dasabuvir (Standard) ABT-333 (Standard)	Reference Standards HCV DNA/RNA Synthesis	Infection
Dasabuvir (Standard) is the analytical standard of Dasabuvir. This product is intended for research and analytical applications. Dasabuvir (ABT-333) is a nonnucleoside *hepatitis C virus (HCV) polymerase* inhibitor. Dasabuvir inhibits RNA-dependent RNA polymerase encoded by the HCV NS5B gene. Dasabuvir inhibits genotype 1a (strain H77) and 1b (strain Con1) replicons, with EC₅₀ values of 7.7 and 1.8 nM, respectively .

HY-115981

NS5A-IN-2	HCV Protease	Infection
NS5A-IN-2 (Compound 33) is a potent inhibitor of NS5A. NS5A-IN-2 has extremely high potency against HCV genotype 1b, improved activity against genotype 3a (GT 3a) and good metabolic stability . NS5A-IN-2 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-10466S1

Daclatasvir-13C2,d6 BMS-790052-¹³C₂,d₆; EBP 883-¹³C₂,d₆	Isotope-Labeled Compounds HCV	Infection
Daclatasvir- ¹³C2,d₆ (BMS-790052- ¹³C2,d₆) is ¹³C and deuterium labeled Daclatasvir. Daclatasvir (BMS-790052) is a potent and orally active HCV NS5A protein inhibitor with EC₅₀s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir is also a organic anion transporting polypeptide 1B (OATP1B) and *OATP1B3* inhibitor with IC₅₀s of 1.5 μM and 3.27 μM, respectively .

HY-108029

Deldeprevir sodium ACH-2684 sodium; Neceprevir sodium	HCV HCV Protease	Infection
Deldeprevir (ACH-2684; Neceprevir) sodium is a HCV NS3/4A protease inhibitor and resistance inhibitor. Deldeprevir sodium exhibits activity against wild-type genotype 1a and 1b *HCV, including mutant strains resistant to other NS3* protease inhibitors. Deldeprevir sodium blocks the emergence of HCV mutant strains resistant to ACH-3422 in vitro, with enhanced efficacy when used in triple combination with ACH-3422 and ACH-3102 (HY-124182). Deldeprevir sodium shows additive antiviral potency when combined with ACH-3422, and exerts antiviral activity against HCV replicons carrying ACH-3102. Deldeprevir sodium is applicable to research related to hepatitis C .

HY-182691

Amphihevir	HCV	Infection
Amphihevir is an orally active HCV NS4B inhibitor. Amphihevir exhibits activity against *HCV* genotype 1a and 1b replicons and reduces *HCV* RNA levels. Amphihevir can be used in the research of chronic hepatitis C .

HY-12731

GSK2236805	HCV	Infection
GSK2236805 is a potent hepatitis C virus inhibitor with pEC₅₀ values of 10.4, 11.1 for HCV genotype 1a (gt1a) and gt1b, respectively .

HY-10246A

A-837093 sodium	HCV DNA/RNA Synthesis	Infection
A-837093 sodium is a potent and orally active inhibitor of the hepatitis C virus (HCV) nonstructural protein 5B (NS5B) polymerase. A-837093 sodium shows potencies against polymerases derived from both HCV genotypes 1a (IC₅₀ = 1.25 nM) and 1b (IC₅₀ = 0.33 nM). A-837093 sodium exhibits antiviral efficacy in HCV-infected chimpanzees. A-837093 sodium can be used for HCV infection research .

HY-123536

AZD2836 A-831	PI4K HCV	Infection
AZD2836 (A-831) is a 4-aminopyrazolone compound with anti-HCV activity. AZD2836 inhibits the activity of the host cell kinase PI4KIIIα, causing metabolic disorder of the cell membrane component PI4P that is necessary for viral replication. In the HCV subgenomic replicon cell model, the EC₅₀ values of AZD2836 for genotype 1b (Con1 strain) and genotype 1a (Lemon strain) are 270 nM and 550 nM, respectively .

HY-10238R

Danoprevir (Standard) ITMN-191 (Standard); R7227 (Standard); RO5190591 (Standard); RG7227 (Standard)	Reference Standards HCV Protease HCV SARS-CoV	Infection
Danoprevir (Standard) is the analytical standard of Danoprevir (HY-10238). This product is intended for research and analytical applications. Danoprevir (ITMN-191) is an orally active NS3/4A protease inhibitor for hepatitis C virus (HCV) with an IC₅₀ of 0.29 nM and is selective for NS3/4A over a panel of 53 proteases (IC₅₀ higher than 10 μM). Danoprevir (ITMN-191) inhibits HCV genotypes 1a, 1b, 4, 5, and 6 (IC₅₀s=0.2-0.4 nM) as well as 2b and 3a (IC₅₀s=1.6, 3.5 nM) . Danoprevir is also a SARS-CoV 3CLpro inhibitor with an IC₅₀ of 0.05 μM .

HY-115516

BI-1388	HCV HCV Protease Ras	Infection
BI-1388 is a macrocyclic acylsulfonamide-based HCV NS3-4A protease inhibitor. BI-1388 inhibits clinically relevant drug-resistant mutant strains (KRAS ^D168V gt 1b and KRAS ^R155K gt 1a) and exhibits high liver distribution. BI-1388 is applicable for the research of HCV infection .

HY-182679

L0909	HCV	Infection
L0909 is an HCV inhibitor with an EC₅₀ of 0.022 μM. L0909 blocks HCV replication by inhibiting E1-mediated viral entry. L0909 exhibits sensitivity to clinical resistant HCV mutants. L0909 displays synergistic effects with clinical HCV drugs. L0909 can be used for the research of hepatitis c virus (HCV) infection .

HY-117802

CID-50930756	DNA/RNA Synthesis HCV HCV Protease	Infection
CID-50930756 is an HCV NS3 helicase inhibitor with an IC₅₀ of 22 μM.CID-50930756 inhibits HCV NS3 helicase-catalyzed nucleic acid unwinding.CID-50930756 inhibits HCV replication in hepatoma cells harboring a stably transfected subgenomic HCV replicon.CID-50930756 does not exhibit toxicity to hepatoma cells at 10 μM.CID-50930756 shows weak DNA-binding activity, displacing less than 20% of SYBR Green I from DNA at 100 μM.CID-50930756 can be used for the research of hepatitis c .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N6798

Myriocin 10+ Cited Publications Thermozymocidin; ISP-I	Infection Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Disease Research Fields Source Classification	HCV Antibiotic
Myriocin (Thermozymocidin), a fungal metabolite could be isolated from Myriococcum albomyces, Isaria sinclairi and Mycelia sterilia, is a potent inhibitor of serine-palmitoyl-transferase (SPT) and a key enzyme in de novo synthesis of sphingolipids. Myriocin suppresses replication of both the subgenomic HCV-1b replicon and the JFH-1 strain of genotype 2a infectious HCV, with an IC₅₀ of 3.5 μg/mL for inhibiting HCV infection .

HY-N6798R

Myriocin (Standard) Thermozymocidin (Standard); ISP-I (Standard)	Structural Classification Microorganisms Ketones, Aldehydes, Acids Source Classification	Reference Standards HCV Antibiotic
Myriocin (Standard) is the analytical standard of Myriocin. This product is intended for research and analytical applications. Myriocin (Thermozymocidin), a fungal metabolite could be isolated from Myriococcum albomyces, Isaria sinclairi and Mycelia sterilia, is a potent inhibitor of serine-palmitoyl-transferase (SPT) and a key enzyme in de novo synthesis of sphingolipids. Myriocin suppresses replication of both the subgenomic HCV-1b replicon and the JFH-1 strain of genotype 2a infectious HCV, with an IC50 of 3.5 μg/mL for inhibiting HCV infection[1][2][3].

Cat. No.	Compare	Product Name	Species	Source	Image

HY-P703547

	HCVNS5B Protein, HCV Genome polyprotein; Hepatitis C virus genotype 1b (strain HC-J4); HCV; p23; Helicase; Hydrolase; Ion channel; Multifunctional enzyme; Nucleotidyltransferase; Protease; Ribonucleoprotein; RNA-binding; RNA-directed RNA polymerase; Serine protease; Thiol protease; Transferase; Viral ion channel; Viral nucleoprotein	Others	E. coli
	POLG proteins play multiple roles in the viral life cycle, contributing to viral RNA packaging, budding, and particle production. It exhibits RNA-binding and RNA chaperone activities, affecting translation initiation through interactions with viral IRES and ribosomal subunits. HCVNS5B Protein, HCV is the recombinant HCVNS5B, expressed by E. coli, with tag-free.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name	Chemical Structure

HY-131905S

BMS-986144
BMS-986144 is a third-generation, pan-genotype (GT) NS3/4A protease inhibitor. BMS-986144 inhibits HCV replicon with EC₅₀s of 2.3, 0.7, 1.0, 12, 8.0, and 5.8 nM for GT-1a, GT-1b, GT-2a, GT-3a, 1a R155X, and 1b D168V, respectively. BMS-986144 has the potential for the research of HCV infection .

HY-10466S

Daclatasvir-d6
Daclatasvir-d₆ is deuterium labeled Daclatasvir. Daclatasvir (BMS-790052) is a potent and orally active HCV NS5A protein inhibitor with EC₅₀s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir is also a organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC₅₀s of 1.5 μM and 3.27 μM, respectively .

HY-10466S2

Daclatasvir-d16
Daclatasvir-d₁₆ is deuterium labeled Daclatasvir. Daclatasvir (BMS-790052) is a potent and orally active HCV NS5A protein inhibitor with EC₅₀s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir is also a organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC₅₀s of 1.5 μM and 3.27 μM, respectively .

HY-10466S1

Daclatasvir-13C2,d6

Daclatasvir- ¹³C2,d₆ (BMS-790052- ¹³C2,d₆) is ¹³C and deuterium labeled Daclatasvir. Daclatasvir (BMS-790052) is a potent and orally active HCV NS5A protein inhibitor with EC₅₀s range of 9-146 pM for multiple HCV replicon genotypes. Daclatasvir is also a organic anion transporting polypeptide 1B (OATP1B) and OATP1B3 inhibitor with IC₅₀s of 1.5 μM and 3.27 μM, respectively .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks